Emmaus Life Sciences Stock

Emmaus Life Sciences ROA 2024

Emmaus Life Sciences ROA

-0.11

Ticker

EMMA

ISIN

US29137T1016

WKN

A2PNWG

In 2024, Emmaus Life Sciences's return on assets (ROA) was -0.11, a -51.85% increase from the -0.22 ROA in the previous year.

Emmaus Life Sciences Aktienanalyse

What does Emmaus Life Sciences do?

Emmaus Life Sciences Inc. is an innovative US-American company that develops, produces, and markets medications based on L-Glutamine. The company was founded in 2000 by Dr. Yutaka Niihara, a Japanese researcher who grew up in the USA and received his doctorate from Harvard Medical School. The idea for founding Emmaus Life Sciences arose from the observation of patients with sickle cell anemia, an inherited blood disease. These patients suffer from intense pain attacks caused by the clumping of red blood cells in the body. Dr. Niihara and his colleagues researched the effects of L-Glutamine on these pain attacks and were able to demonstrate that L-Glutamine can significantly reduce the frequency and intensity of the pain attacks. Based on these research results, Emmaus Life Sciences developed the medication "Endari," which was approved by the US-American regulatory authority FDA in 2017. "Endari" is the first medication specifically approved for the treatment of sickle cell anemia. It is intended to reduce the frequency and severity of pain attacks in patients with sickle cell anemia. Since its founding in 2000, Emmaus Life Sciences has expanded significantly. The company now has multiple locations in the USA and employs over 150 employees. Emmaus Life Sciences operates in two business areas: medications and health products. In the medication area, Emmaus Life Sciences focuses on the development of drugs for rare diseases. In addition to "Endari," the company is working on the development of medications for the treatment of mucopolysaccharidosis (MPS) and acid peptidase deficiency (ASM). In the health products area, Emmaus Life Sciences specializes in the production and marketing of dietary supplements. The company has developed a range of products based on L-Glutamine as the active ingredient. These products are intended to support the health of athletes, people with special dietary needs, older adults, and people with certain diseases. Emmaus Life Sciences' products include L-Glutamine powder for daily use, L-Glutamine capsules for athletes and bodybuilders, L-Glutamine for clinical nutrition, and a special L-Glutamine product for people with chronic kidney disease. Emmaus Life Sciences is an innovative company that builds its products on scientifically validated research results. The company specializes in the development of medications and health products that help people improve their health and increase their quality of life. Emmaus Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Emmaus Life Sciences's Return on Assets (ROA)

Emmaus Life Sciences's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Emmaus Life Sciences's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Emmaus Life Sciences's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Emmaus Life Sciences’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Emmaus Life Sciences stock

What is the Return on Assets (ROA) of Emmaus Life Sciences this year?

The Return on Assets (ROA) of Emmaus Life Sciences is -0.11 undefined this year.

What was the ROA of Emmaus Life Sciences compared to the previous year?

The ROA of Emmaus Life Sciences has increased by -51.85% compared to the previous year.

What consequences do high ROA have for investors of Emmaus Life Sciences?

A high ROA is advantageous for investors of Emmaus Life Sciences, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Emmaus Life Sciences?

A low ROA can be unfavorable for investors of Emmaus Life Sciences as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Emmaus Life Sciences affect the company?

An increase in ROA of Emmaus Life Sciences can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Emmaus Life Sciences impact the company?

A reduction in the ROA of Emmaus Life Sciences can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Emmaus Life Sciences?

Some factors that can influence the ROA of Emmaus Life Sciences include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Emmaus Life Sciences important for investors?

The ROA of Emmaus Life Sciences is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Emmaus Life Sciences take to improve ROA?

To improve ROA, Emmaus Life Sciences can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Emmaus Life Sciences pay?

Over the past 12 months, Emmaus Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emmaus Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Emmaus Life Sciences?

The current dividend yield of Emmaus Life Sciences is .

When does Emmaus Life Sciences pay dividends?

Emmaus Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emmaus Life Sciences?

Emmaus Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Emmaus Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emmaus Life Sciences located?

Emmaus Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emmaus Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emmaus Life Sciences from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Emmaus Life Sciences pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Emmaus Life Sciences in the year 2023?

In the year 2023, Emmaus Life Sciences distributed 0 USD as dividends.

In which currency does Emmaus Life Sciences pay out the dividend?

The dividends of Emmaus Life Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Emmaus Life Sciences

Our stock analysis for Emmaus Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emmaus Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.